1042 GMT - Novartis exceeded expectations with profit and sales figures, accompanied by an improved outlook, defying concerns about upcoming generic competition in the U.S. for three of its key products, Vontobel analyst Stefan Schneider says in a note. "With the generic entry to three Novartis products still expected per mid-year, the guidance increase appears to us as a very confident sign that the company's growth drivers are expected to perform well also during the remainder of the year," he says. The Swiss drugmaker hereby signals that it can comfortably overcompensate the expected generic erosion, he says. Shares rise 1.1% to 94.43 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 29, 2025 06:42 ET (10:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。